Lateral Flow Assays Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Lateral Flow Assays Market in 2025 is estimated at USD 13.54 billion. The global Market size was valued at around USD 12.76 billion in 2024 and is projected to grow at a CAGR of more than 7.6%, reaching USD 33.07 billion revenue by 2037. Asia Pacific is poised to attain USD 11.24 billion by 2037, driven by high burden of infectious diseases, driving the need for lateral flow testing.
The growth of the market is mainly due to the increasing prevalence of infectious diseases. According to the World Health Organization (WHO), infectious diseases are the leading cause of death worldwide, accounting for about 25% of all deaths worldwide.
Increasing demand for diagnostic test products that use lateral flow technology for the detection of diseases, is further predicted to drive the lateral flow assays market. In 2020, an estimated 38 million people were living with HIV/AIDS worldwide, with 1.5 million new infections and 690,000 deaths. Tuberculosis (TB) remains one of the top 13th causes of death globally with about 10.6 million new cases and 1.6 million deaths in 2021.
Lateral Flow Assays Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Research Costs – The growth of the global lateral flow assays market is driven by increased investment in research and development activities. This helps to find more viable solutions for biosafety cabinets. Research reports show that global R&D spending has grown from around USD 680 billion to over USD 2.5 trillion in 2020.
- Growing Demand for Point-of-the-Care Testing – Point-of-the-care diagnostics devices have become increasingly important in recent years due to their ability to provide fast and accurate results in a variety of environments. Lateral flow assays are well suited to POCTs due to their simplicity, portability, and ease of use.
- Growing Demand for Food Safety Testing - The demand for food safety testing is increasing globally, due to factors such as the increasing incidence of foodborne illnesses, and safety regulations. Food changes and consumer awareness is increasing about the safety and quality of the food they eat. Side flow testing is widely used for food safety testing due to its ease of use, fast turnaround time, and ability to detect a wide range of contaminants such as pathogens, toxins, and allergens.
Challenges
- Lack of Sensitivity and Specificity – Lateral flow assays are known to have limitations in terms of sensitivity and specificity compared to other diagnostic methods, such as PCR or ELISA. This can lead to false-positive or false-negative results, which can be a significant challenge in various applications.
- Competition from Substitute Technologies
- Regulatory Limitations Associated
Lateral Flow Assays Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.6% |
|
Base Year Market Size (2024) |
USD 12.76 billion |
|
Forecast Year Market Size (2037) |
USD 33.07 billion |
|
Regional Scope |
|
Lateral Flow Assays Segmentation
End Users (Hospitals, Diagnostic Laboratories, Pharmaceutical Companies)
The diagnostic laboratory segment is estimated to hold the largest share of the lateral flow assays market during the time period. The growth of the segment is driven by increased demand for flow analysis testing. Moreover, for any viral spread of infections, lateral flow tests are used by various institutions and governments to confirm symptomatic and asymptomatic infections.
Product (Kits & Reagents, Lateral Flow Readers)
Lateral flow assays (LFA) market from the kits and reagents segment is set to occupy a noteworthy gain of 60% by the end of 2037. The growth of this segment is driven by the growing demand for rapid anti-care tests. These products are widely used in different environments, such as clinics, hospitals, and home testing, due to their simplicity, ease of use, and anti-fast turnaround times. The growth of new innovative anti-horizontal scanning technologies, such as smartphone-based anti-flow digital scanning, is also driving demand for kits and reagents.
Our in-depth analysis of the global lateral flow assays (LFA) market includes the following segments:
|
Product |
|
|
End Users |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportLateral Flow Assays Landscape – Regional Synopsis
APAC Market Forecasts
The Asia-Pacific lateral flow analysis market is predicted to hold the largest share of 34% during the assessment period. The Asia-Pacific region has a high burden of infectious diseases, which is driving the need for lateral flow testing for rapid and accurate diagnosis. Several countries in the Asia-Pacific region such as China and India are investing heavily in health infrastructure.
North American Market Statistics
The North America lateral flow analysis market is assumed to hold a notable share of 26 % during the forecast period. North America is at the heart of technological advancements, driving the development of new and innovative transverse flow analysis technologies, and is anticipated to drive the growth of the market in the region.
Companies Dominating the Lateral Flow Assays (LFA) Market
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Becton, Dickinson, and Company
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- F.Hoffmann-La Roche AG
- QIAGEN N.V.
- Siemens Healthineers AG
- Thermo Fisher Scientific, Inc.
- Merck kGaA
- PerkinElmer Inc.
In the News
- Abbott Laboratories announced the launch of a new lateral flow antigen test called the BinaxNOW COVID-19 Ag Card home test. This test is intended for non-prescription, and over-the-counter use, and provides results in 15 minutes. It is the first COVID-19 test authorized for non-prescription use by the US Reel and Drug Administration (FDA).
- Becton, Dickinson, and Company: SD announced the acquisition of a lateral now and clinical diagnostics company, Infiammatix. Inflammatix's technology enables rapid diagnosis and triage of patients with suspected infectious or inflammatory conditions. The acquisition is expected to enhance BD's diagnostic capabilities and expand its presence in the infectious disease market.
Author Credits: Radhika Pawar
- Report ID: 4871
- Published Date: May 09, 2025
- Report Format: PDF, PPT
